Memphasys Secures Vietnam Registration and First 600-Cartridge Felix Order

Vietnam Registration Unlocks Commercial Sales

Memphasys Limited (ASX:MEM) has hit a critical milestone with regulatory registration of its Felix™ sperm selection system in Vietnam, achieved in August 2026 as planned. This clearance opens the door for full commercial sales in one of South-East Asia’s fastest expanding assisted reproductive technology (ART) markets, a region seeing rising healthcare investment and fertility service demand.

The registration immediately triggered a first commercial order from TMSC Vietnam for 600 Felix™ cartridges. This order supplements an earlier delivery of 100 cartridges and three consoles provided for clinical preparation and in-market testing, bringing the total cartridges supplied or ordered for Vietnam to 700. The transition from pre-launch testing to full commercial supply marks a tangible step forward in Memphasys’ international rollout.

Early Clinical Success Supports Market Introduction

TMSC Vietnam, the exclusive commercialisation partner under a two-year A$530,000 agreement, has begun introducing Felix™ to fertility clinics across Hanoi and Ho Chi Minh City. Notably, the partner reported the first successful pregnancy resulting from the system’s use in a Vietnamese clinic within just three weeks of engagement. While a single clinical outcome does not predict broader results, it provides an encouraging signal as Memphasys and TMSC ramp up market penetration.

Memphasys’ commercial model leverages TMSC’s local regulatory expertise and established reproductive health networks to build clinic adoption, while Memphasys focuses on product education and clinical positioning. The contract’s quarterly cartridge volumes are set to increase alongside clinical uptake, reflecting a scalable revenue stream as adoption grows.

Vietnam Joins Expanding South-East Asian Footprint

The Vietnam deal complements Memphasys’ broader regional expansion, following recent agreements in Thailand and Poland. These contracts contribute to a growing portfolio of multi-year exclusive commercialisation arrangements that underpin the company’s strategy to establish Felix™ as a global standard in sperm preparation for ART. The Vietnam market, with its expanding fertility infrastructure and rising demand, represents a significant commercial opportunity within this growth trajectory.

Memphasys’ recent quarterly results highlighted accelerating commercial momentum, with record revenues and multiple new contracts across key markets. The Vietnam registration and cartridge order reinforce this positive trend, underpinning expectations for recurring revenue streams as the Felix™ System gains clinical traction.

Next Steps in Commercial Rollout

With regulatory approval secured, Memphasys and TMSC Vietnam will focus on converting early clinic interest into broader adoption and sustained cartridge sales. The company will continue to support training and education efforts to facilitate clinical integration. Future updates will likely track quarterly sales volumes and market penetration metrics, which will be critical to assessing the commercial impact of this milestone.